Open access · US-GOV via ClinicalTrials.gov Clinical trial

Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients; Double-blinded Randomized Controlled Trial

Authors not listed

Yonsei University · 2024

Dysbiosis Human Randomized controlled trial

Abstract

This study aims to investigate the potential improvement in muscle function, compared to the placebo group, through the concurrent administration of denosumab and alfacalcidol over a one-year period in postmenopausal women with functional sarcopenia and osteoporosis aged 65 and older. The study is planned as a double-blinded randomized controlled trial, intending to recruit a total of 340 participants. Primary outcome is the improvement in SPPB score of 0.5 or more compared to the control group.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-27 MST

Cite this

APA

Anonymous. (2024). Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients; Double-blinded Randomized Controlled Trial. <em>Yonsei University</em>. https://clinicaltrials.gov/study/NCT06272227

Vancouver

Anonymous. Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients; Double-blinded Randomized Controlled Trial. Yonsei University. 2024.

BibTeX

@misc{anon2024Effect, title = {Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients; Double-blinded Randomized Controlled Trial}, author = {Anonymous}, journal = {Yonsei University}, year = {2024}, }